INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 415m ago
HOUSE PTR15m ago
SEC 13F15m ago
ROBINHOOD CHAIN14m ago
Corporate insider
VL

Vairavan Latha

SVP Chief Financial OfficerCIK 0002065881

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 3
Max Insider Score20
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
VL
Vairavan LathaSVP Chief Financial Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$9,157
435 sh
May 11, 2026May 13, 2026
traded May 11, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Arcutis Biotherapeutics, Inc.SVP Chief Financial Officer · Nov 5, 2025
11
VL
Vairavan LathaSVP Chief Financial Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$32K
1,341 sh
May 4, 2026
May 6, 2026
traded May 4, 2026
+2d
SEC FORM 4

Evidence

20
VL
Vairavan LathaSVP Chief Financial Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$2,175
88 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence